These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9625535)

  • 1. Tumour cell resistance to non-MHC-restricted lymphocytes: molecular mechanisms and clinical implications.
    Tagliaferri P; Guarrasi R; Caraglia M; Morelli D; Fabbrocini A; Correale P; Bianco AR
    Cancer Immunol Immunother; 1998 May; 46(3):121-7. PubMed ID: 9625535
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy.
    Fischer B; Müller B; Fisch P; Kreutz W
    J Immunother; 2000; 23(2):196-207. PubMed ID: 10746546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of effector mechanisms in cancer.
    Lotzová E
    Curr Opin Immunol; 1989 Jun; 1(5):904-9. PubMed ID: 2679738
    [No Abstract]   [Full Text] [Related]  

  • 6. An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells.
    Müller B; Fischer B; Kreutz W
    Immunology; 2000 Mar; 99(3):375-84. PubMed ID: 10712667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients.
    Schendel DJ; Falk CS; Frankenberger B; Noessner E; Schleypen J; Pohla H
    Urologe A; 2004 Sep; 43 Suppl 3():S133-5. PubMed ID: 15179552
    [No Abstract]   [Full Text] [Related]  

  • 8. An analysis of the relationship between gamma delta T cell receptor V gene usage and non-major histocompatibility complex-restricted cytotoxicity.
    Mavaddat N; Robinson BW; Rose AH; Manning LS; Garlepp MJ
    Immunol Cell Biol; 1993 Feb; 71 ( Pt 1)():27-37. PubMed ID: 8436409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro.
    Slovin SF; Maguire HC; Mastrangelo MJ
    Cancer; 1990 Dec; 66(12):2541-6. PubMed ID: 2123415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2, killer cells and cancer therapy: an overview.
    Parkinson DR; Lotzová E
    Nat Immun Cell Growth Regul; 1990; 9(4):237-41. PubMed ID: 2215512
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy.
    Lotzová E
    Leuk Lymphoma; 1992 May; 7(1-2):15-28. PubMed ID: 1472926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
    Fiorentino B; Di Stefano P; Giuliani C; Amatetti C; Tinari N; Natoli C; Garufi C; Iacobelli S
    Br J Cancer; 1992 Nov; 66(5):981-3. PubMed ID: 1419647
    [No Abstract]   [Full Text] [Related]  

  • 13. Adoptive cellular immunotherapy of cancer.
    Winter H; Fox BA
    Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
    [No Abstract]   [Full Text] [Related]  

  • 14. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC gene control of the natural killer system at the level of the target and the host.
    Kärre K
    Semin Cancer Biol; 1991 Oct; 2(5):295-309. PubMed ID: 1773046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo generation, enhancement and recruitment of host cellular immune responses against tumor: influence of MHC antigen expression on clones of tumor cell variants.
    Fernández-Cruz E; Pérez M; Zabay JM; Garrido F
    Prog Clin Biol Res; 1987; 244():115-25. PubMed ID: 2958867
    [No Abstract]   [Full Text] [Related]  

  • 17. Adoptive immunotherapy for cancer.
    Rosenberg SA
    Sci Am; 1990 May; 262(5):62-9. PubMed ID: 2333496
    [No Abstract]   [Full Text] [Related]  

  • 18. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy.
    Schendel DJ; Oberneder R; Falk CS; Jantzer P; Kressenstein S; Maget B; Hofstetter A; Riethmüller G; Nössner E
    J Mol Med (Berl); 1997 Jun; 75(6):400-13. PubMed ID: 9231880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells.
    Karlhofer FM; Ribaudo RK; Yokoyama WM
    Nature; 1992 Jul; 358(6381):66-70. PubMed ID: 1614533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of nonspecific cell-mediated cytotoxicity: a multisignal event and its cellular regulation.
    Atzpodien J; Bührer C; Gulati SC; Wisniewski D; Oz S; Kirchner H; Benter T; Poliwoda H; Welte K; Clarkson B
    Haematol Blood Transfus; 1989; 32():273-80. PubMed ID: 2625252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.